Global Cancer Profiling Market Size study & Forecast, by Technology (Immunoassays, Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Microarrays, and Others), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, and Othe

Global Cancer Profiling Market Size study & Forecast, by Technology (Immunoassays, Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Microarrays, and Others), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, and Others), Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Others), and Regional Analysis, 2023-2030

Global Cancer Profiling Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.8% over the forecast period 2023-2030. Cancer profiling involves the study of genetic, genomic, proteomic, and epigenetic alterations in cancer cells to understand their unique characteristics, behavior, and potential response to specific treatments. The goal of cancer profiling is to provide personalized and targeted therapies for cancer patients based on the molecular profile of their tumors. The market growth is driven by key factors such as increasing incidence of cancer, government investment on healthcare infrastructure and increasing Cancer Research and Funding.

GLOBOCAN 2020 report from the International Agency for Research on Cancer estimated the incidence and mortality of 36 cancers in 185 countries. There were reportedly 19,292,789 new cases of cancer diagnosed in 2020 and roughly 9,958,133 cancer-related deaths globally. Males made up 10,065,305 of the total diagnosed cancer cases, while females made up 9,227,484 of those incidents. Furthermore, as per the publishing year 2021, According to Invest India’s Investment Grid, there are nearly 600 investment opportunities value USD 32 Billion in the country’s hospital/medical infrastructure sub-sector. Moreover, growth in the use of next-generation sequencing technique for cancer Profiling and significant development of precision medicine create lucrative growth opportunities for the market in the forecast years. However, high Capital Investment stifles the market growth throughout the forecast period of 2023-2030

The key regions considered for the Global Cancer Profiling Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is leading the global market with largest share owing to new product launches and increase in incidence of cancer disease. However, Asia Pacific is expected to be the fastest growing region owing to advanced cancer testing and development in precision medicine in the region.



Major market player included in this report are:
Predictive Oncology
Caris Life Sciences
F. Hoffmann-La Roche Ltd
GenScript Biotech
Guardant Health
Hologic, Inc
HTG Molecular Diagnostics, Inc.
Illumina, Inc
NanoString Technology
NeoGenomics Laboratories



Recent Developments in the Market:
 In January 2022, A strategic partnership between NeoGenomics, Inc. and the Biomarker to make it easier for cancer patients who test positive for particular biomarkers to get in touch with support groups that also include other patients who have the same results. NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing services and global oncology contract research services.

Global Cancer Profiling Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Technology, Cancer Type, Biomarker Type, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:
Immunoassays
Next Generation Sequencing
Polymerase Chain Reaction
In Situ Hybridization
Microarrays
Others
By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Others
By Biomarker Type:
Genetic Biomarkers
Protein Biomarkers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Companies Mentioned
Predictive Oncology
Caris Life Sciences
F. Hoffmann-La Roche Ltd
GenScript Biotech
Guardant Health
Hologic, Inc
HTG Molecular Diagnostics, Inc.
Illumina, Inc
NanoString Technology
NeoGenomics Laboratories

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.